Preliminary Program Outline

Wednesday, September 3, 2003
3:00 pm–5:00 pm Conference Center Registration Desk:	=	AACT Pre‐Meeting Symposium: From Cradle to Grave: Recent Developments in Clinical Toxicology Registration/Information

Thursday, September 4, 2003
7:00 am–6:00 pm Conference Center Meeting Office:	=	Speaker Ready Room
7:00 am–8:00 am Conference Center Registration Desk:	=	AACT Pre‐Meeting Symposium: From Cradle to Grave: Recent Developments in Clinical Toxicology Registration/Information
7:00 am–8:00 am Conference Center Foyer:	=	Continental Breakfast
8:00 am–4:00 pm Conference Center Room 10:	=	AACT Pre‐Meeting Symposium: From Cradle to Grave: Recent Developments in Clinical Toxicology, Moderators: Gary S. Wasserman, DO and Ruth A. Lawrence, MD (AM) Eric Lavonas, MD and Donna Seger, MD (PM) Determinants of Pediatric Xenobiotic Exposure: Development and Pharmacogenetics, Gregory Kearns, PharmD, PhD, University of Missouri‐Kansas City Unlocking the Secrets of the Genome: Pharmacogenomics at the Fetal‐Neonatal Interface, J. Steven Leeder, PharmD, PhD, University of Missouri‐Kansas City Advances in Management of Critical Pediatric Poisonings, William Banner, MD, PhD, Oklahoma University College of Medicine—Tulsa The Chernobyl Reactor Accident: Health Effects in Children, Daniel Hryhorczuk, MD, MPH, FACMT, University of Illinois at Chicago Update on Smallpox Vaccination Trials, Kathryn Edwards, MD, Vanderbilt University The Role of the Poison Center in BioChemical Terrorism, Philip Edelman, MD, Centers for Disease Control and Prevention Toxicities of Therapeutic Agents in the Elderly—and How to Minimize or Prevent Them, Seymour Ehrenpreis, PhD, Chicago Medical School Antenatal Exposures: Pathway to Adult Neurodegenerative Disease, Paul Carvey, PhD, Rush Medical College The participant at the end of this session should be able to: Define the age‐related breakpoints for important drug biotransformation pathways. Examine the inter‐relationship of ontogeny and pharmacogenetics as it pertains to ontogeny of drug biotransformation. Apply pharmacogenetic and pharmacokinetic principles to characterize drug exposure and effect. Define pharmacogenomics and pharmacogenetics in a developmental context. Review strategies that can be used to characterize the global response to xenobiotic challenge and prioritize pharmacogenomic studies of drug‐induced birth defects in humans. Evaluate new measures to support children with ARDS following toxin induced lung injury. Discuss the application of ECMO to the support of patients with cardiovascular failure. Evaluate the effectiveness of continuous renal replacement therapies in removing toxins Discuss the causes of the Chernobyl reactor accident and how these types of accidents can be prevented. Differentiate the types of Chernobyl radiation exposure and their health consequences. Describe the design and preliminary findings of the major longitudinal studies on children's exposure to Chernobyl radiation that are currently underway. Summarize the role of smallpox vaccination, reported and potential adverse events as well as current status of the smallpox trials. Describe the role of poison centers' capacity for real‐time disease surveillance in the early detection of biological or chemical terrorism events. Identify common and significant drug‐herb interaction in the elderly. Critique the data linking antenatal toxic exposures and adult‐onset Parkinson's Disease.
12:30 pm–6:00 pm Conference Center Room 21 A:	=	ABAT Certification Examination
3:00 pm–6:00 pm Conference Center Registration Desk:	=	ACMT Pre‐Meeting Symposium: Law and Order—Legal Issues In Medical Toxicology Registration/Information
7:00 pm–9:00 pm Conference Center Room 11:	=	AAPCC Council of Medical Directors

Friday, September 5, 2003
7:00 am–6:00 pm Conference Center Meeting Office:	=	Speaker Ready Room
7:00 am–8:00 am Conference Center Registration Desk:	=	ACMT Pre‐Meeting Symposium: Law and Order—Legal Issues In Medical Toxicology Registration/Information
7:00 am–8:00 am Conference Center Foyer:	=	Continental Breakfast
8:00 am–1:00 pm Conference Center Room 21 A:	=	ABAT Certification Examination
8:00 am–4:30 pm Conference Center Room 11 A:	=	AAPCC CSPI Exam Committee Workshop
8:00 am–4:30 pm Conference Center Room 10:	=	ACMT Pre‐Meeting Symposium: Law and Order—Legal Issues In Medical Toxicology, Moderators: Lewis S. Nelson, MD, Holly Perry, MD, and Stephen Traub, MD So Sue Me! Toxicology Traps for Poison Centers & How To Avoid Them!, Alan Woolf, MD, Children's Hospital, Boston The Legal Implications of Current Emergency Medical Practice, Richard Hamilton, MD, Drexel University College of Medicine Evidentiary Standards for Toxicologists, A. Nelson Avery, MD, University of Texas—Galveston Medical Toxicology and the Consumer Product Safety Commission, a Successful Partnership in Poison Prevention, John Boja, PhD, US Consumer Products Safety Commission Does It Matter If Ephedrine Is Safe? Regulatory Issues and the FDA, Christine Haller, MD, University of California, San Francisco The Legal Hurdles Faced by the Institutional Review Board, Jack Snyder, MD, JD, National Library of Medicine Above The Law: The Interface Between Toxicologists and the DEA, Chris Trojan, Drug Enforcement Administration Panel Discussion The participant at the end of this session should be able to: Discuss the liability issues surrounding the provision of medical advice and phone consultation for Poison Control personnel and how to reduce them. Identify legal challenges encountered when caring for intoxicated patients in the emergency department and understand how to handle them. Summarize the legal standard for admitting expert scientific testimony according to the Daubert opinion. Recognize how medical professionals can work with the Consumer Product Safety Commission to protect the public from potentially poisonous consumer products. Review the Dietary Supplement Health and Education Act and understand how it affects regulation of ephedrine containing products. Discuss the role of the Institutional Review Board in protecting patients. Describe how toxicologists and poison control centers interface with the Drug Enforcement Administration. Discuss the potential impact on the IRB on the protection of patients and the limitation of research.
8:00 am–5:00 pm Conference Center Room 21AB:	=	ABAT Board Meeting
4:30 pm–6:30 pm Conference Center Room 10:	=	ACMT Medical Toxicology CPC Competition Case Discussants, Moderators: Jeffrey Suchard, MD and Joseph Rella, MD The participant at the end of this session should be able to: Formulate an approach to the diagnosis of complex poisoning cases based on limited data. Describe the management of several unique poisonings. Identify potential pitfalls in the diagnostic approach to poisoned patients.
12:00 pm–5:00 pm Conference Center Room 12:	=	Exhibit Set‐up/Poster Session I Set‐Up
1:00 pm–6:00 pm Conference Center Registration Desk:	=	NACCT Main Congress Registration/Information
4:00 pm–5:00 pm Conference Center Room 12:	=	Poster Session I Set‐Up
4:00 pm–5:30 pm Conference Center Room 22 AB:	=	Poison Center Educator Orientation
5:00 pm–12:00 am Conference Center Room 24 AB:	=	AACT Board Meeting
5:00 pm–11:00 pm Conference Center Room 23 AB:	=	AAPCC Regional Poison Center Certification Committee Meeting
5:00 pm–7:00 pm Conference Center Room 11 B:	=	AAPCC Veterinary Committee
5:00 pm–7:00 pm Conference Center Room 22 C:	=	AAPCC CSPI Exam Committee
6:30 pm–8:00 pm Conference Center Foyer:	=	Opening Reception
6:30 pm–9:30 pm Conference Center Room 21 AB:	=	Public Education Committee Meeting
7:00 pm–11:00 pm Conference Center Room 20 AB:	=	AAPCC Specialist in Poison Information Committee
7:00 pm–9:00 pm Conference Center Room 11 B:	=	AAPCC Data Collection Subcommittee Research
7:00 pm–9:00 pm Conference Center Room 11 A:	=	AAPCC Data Collection Subcommittee Quality Assurance
7:00 pm–9:00 pm Conference Center Room 22 C:	=	AAPCC Data Collection Subcommittee Computerization
9:00 pm–11:00 pm Conference Center Room 11 B:	=	AAPCC Managers Subcommittee Quality Assurance and Benchmarking
9:00 pm–11:00 pm Conference Center Room 23 C:	=	AAPCC Managers Subcommittee Staff Development

Saturday, September 6, 2003
7:00 am–6:00 pm Conference Center Meeting Office:	=	Speaker Ready Room
7:00 am–5:00 pm Conference Center Registration Desk:	=	Registration/Information
7:00 am–8:00 am Hotel Regency Ballroom Foyer:	=	Continental Breakfast
8:15 am–10:15 am Hotel Regency Ballroom AB:	=	AACT Acute/Intensive Care Symposium, Moderators: Leslie R. Dye, MD and Anthony Scalzo, MD Pediatric Methylsalicylate Toxicity, Paul Dargan, MD, National Poisons Information Service (London) Oral Hypoglycemic Toxicity, Tri Tong, MD, University of California, San Diego Neonatal Lead Toxicity, Howard Greller, MD, NYC Poison Control Center Panel Discussants, Paul Wax, MD, Medical Toxicology, Banner Health Milton Tenenbein, MD, Manitoba Poison Center, Michael Shannon, MD, Boston Children's Hospital The participant at the end of this session should be able to: Discuss the treatment of elevated blood lead in pregnancy. Review the treatment of neonatal lead toxicity. Determine the appropriate treatment of pediatric methylsalicylate toxicity. Describe airway management options in an 18 month old with altered mental status. Review the treatment of pediatric oral hypoglycemic ingestion.
8:15 am–10:15 am Hotel Regency Ballroom CDE:	=	AACT Occupational/Environmental Symposium: Neurotoxicology and Causality, Moderator: Alvin C. Bronstein MD Cause and Defect—Clinical versus Laboratory Causation in Neurotoxic Exposures, David Hartman, PhD, Medical and Forensic Neuropsychology The participant at the end of this session should be able to: Define neuropsychology. List three principles if causation. Describe three neuropsychological tests. List three constraints of neuropsychological testing. Give one case example. Compare and contrast clinical versus laboratory (experimental) causation.
8:15 am–10:15 am Conference Center Room 10:	=	CDC/NIOSH Workshop: Antineoplastic Drug Exposures in the Workplace, Moderator: Michael Ottlinger, PhD Anti‐neoplastic Drug Exposures in Health Care Providers, Thomas Conner, PhD, NIOSH Health Effects and Occupational Exposure to Hazardous Drugs, Melissa McDiarmid, MD, MPH, University of Maryland The participant at the end of this session should be able to: Recognize the toxicity of antineoplastic agents and other hazardous drugs. Identify problems associated with handling antineoplastic agents. Name sources of exposure to antineoplastic drugs. Evaluate control measures for handling antineoplastic drugs.
8:30 am–9:00 am Conference Center Room 20:	=	Public Educators Welcome/Continental Breakfast
8:45 am–10:15 am Conference Center Room 20:	=	PEC—Marketing and Public Relations
10:00 am–5:00 pm Conference Center Room 12:	=	Exhibits/Poster Session I Acute Intensive Care Abstracts #1–60 1. FOXY METHOXY: A NEW DRUG OF ABUSE, Smolinske S, Rastogi R, Schenkel S. 2. SEROTONIN SYNDROME FOLLOWING INITIATION OF ESCITALOPRAM MONOTHERAPY FOR DEPRESSION, Wiegand T, Stuart, D. 3. PEDIATRIC OVERDOSE OF DESMOPRESSIN ACETATE, Sigg T, Burda AM, Aks S. 4. CONSTRUCTION OF A NOVEL PREDICTOR OF HEPATOTOXICITY FOLLOWING ACETAMINOPHEN OVERDOSE: BEYOND THE NOMOGRAM, Sivilotti MLA, Good AM, Juurlink DN, Yarema MC, Johnson DW. 5. DELAYED PRESENTATION OF METHANOL INGESTION LEADING TO CEREBRAL HERNIATION AND FATALITY IN THREE OF FOUR SEVERE CASES, Stremski E, Kostecki E, Gummin D. 6. A CASE SERIES OF DERMAL ACETONITRILE EXPOSURES, Tsutaoka BT, Anderson IB, Olson KR. 7. MEDICATION ERRORS IN CHILDREN AGE 5 YEARS AND YOUNGER, Stremski E, Andreson S. 8. ANILINE AND METHANOL TOXICITY AFTER SHOE DYE INGESTION, Katz K, Ruha AM, Curry S, Schwaner R. 9. DELAYS TO ACTIVATED CHARCOAL IN THE ED: WHY BOTHER?, McKinney PE, Wares JB, Crandall C. 10. GHB‐ASSOCIATED VENTRICULAR TACHYCARDIA AND QT PROLONGATION, Suchard JR, Attai S. 11. A 2 YEAR REVIEW OF PIOGLITAZONE AND ROSIGLITAZONE INGESTIONS, Burkhardt CB, Anderson IB. 12. AN OUTBREAK OF SEVERE RODENTICIDE POISONING IN NORTH VIETNAM CAUSED BY ILLEGAL FLUOROACETATE, Höjer J, Hung HT, Du NT, Kylin H, Rosling H. 13. XYLAZINE INJECTION IN MAN, Wolowich WR, McPeak J, Good TG, Casavant MC. 14. PHYSOSTIGMINE ADMINISTRATION FOR QUETIAPINE TOXICITY, Watts D Wax, P. 15. ACUTE RENAL FAILURE, NEUROPATHY AND MYOPATHY AFTER INGESTION OF DIPROPYLENE GLYCOL‐CONTAINING FANTASIA™ FOG SOLUTION, LoVecchio F, Watts D, Curry SC, Wallace KW. 16. ARIPIPRAZOLE (ABILIFY™) OVERDOSE IN A 2.5 YEAR‐OLD, Seifert SA. 17. MASSIVE VERAPAMIL PHARMACOBEZOAR RESULTING IN ESOPHAGEAL PERFORATION, Schwartz MD, Morgan BW. 18. ATROPINE OVERDOSE FROM A SUPPOSITORY COMPOUNDING ERROR, Seifert SA, Caravati EM, Crouch DJ. 19. INCIDENCE OF GRANDPARENT'S ORAL HYPOGLYCEMIC MEDICATIONS AS A SOURCE OF PEDIATRIC INGESTIONS, Alsop JA, Welch RA. 20. UNEXPLAINED PROLONGED INRS IN A COLLEGE STUDENT, Alsop JA, Tegzes JM, Ferguson TJ. 21. SUICIDE FROM TILMICOSIN INJECTION: CASE REPORT AND BLOOD LEVELS, Mueller C, Bottei E. 22. TREATMENT OF DERMAL EXPOSURE TO COMMON HOUSEHOLD ITEMS, Gunia P, Gray J, Gottsch S, Kalin L, Ringling S, Bottei E. 23. DELAYED ONSET OF SEIZURE IN A BODY STUFFER, Yao IC, Mazor SS, O'Koren, K, Guffey, MA, Aks SE, Leikin JB. 24. SHOULD ALL PATIENTS WITH DRUG OVERDOSE HAVE A SALICYLATE LEVEL?, Wood DM, Dargan PI, Jones A. 25. POISONED PATIENTS AS POTENTIAL ORGAN DONORS, A POSTAL SURVEY OF TRANSPLANT CENTRES AND INTENSIVE CARE UNITS, Wood DM, Dargan PI, Jones AL. 26. UNINTENTIONAL ACUTE CATAPRES® PATCH INGESTION IN AN ADULT, Blume C, Menendez J, Scalzo A. 27. TRANSAMINASE ELEVATION IN PYRETHROID INTOXICATIONS, Naumovski J, Krenzelok EP, Bozinovska C, Pereska Z, Kovkarova E. 28. ESTIMATING POPULATION PHARMACOKINETIC PARAMETERS WHEN DOSE AND DOSE‐TIME ARE NOT KNOWN ACCURATELY, Duffull SB, Isbister GK, Dawson AH, Hackett LP, Whyte IM. 29. A CASE OF TYPE F BOTULISM IN SOUTHERN CALIFORNIA, Richardson WH, Frei SS, Williams SR. 30. ACCIDENTAL INGESTION OF CAYENNE PEPPER SAUCE REQUIRING PROLONGED VENTILATORY SUPPORT, Swami RH, Judge BS, Furbee RB. 31. INHALATION ABUSE OF METHANOL‐CONTAINING CARBURETOR CLEANERS, Schaeffer S, McGoodwin L, Riley M. 32. OUTCOME OF HEROIN BODY STUFFERS: A CASE SERIES, Jordan MT, Bryant SM, Aks SE, Wahl M. 33. SEVERE NAPROXEN OVERDOSE WITH ELEVATED SERUM LEVELS, Mullen WM, Meier KM, Hagar SM, Olson KR. 34. “ECSTASY” AND METHAMPHETAMINE RELATED HYPERTHERMIA, Smolinske S, Baltarowich L, Thomas R. 35. A PROSPECTIVE POISON CENTER EXPERIENCE OF SUSTAINED‐RELEASE BUPROPION OVER 40‐MONTHS IN CHILDREN, LoVecchio F, Hilder R, Ruha AM. 36. DIPHENHYDRAMINE‐INDUCED WIDE COMPLEX TACHYCARDIA SHOWN BY EXERCISE TREADMILL TESTING NOT TO BE ENTIRELY RATE RELATED, Schneir AB, Munday S, Ly BT, Williams SR, Clark RF. 37. ACUTE CERAMIC GLAZE INGESTION RESULTING IN LEAD POISONING, Piper D, Krantz A, Bryant SM, Burda A, Restuccia R. 38. HYPERPHOSPHATEMIA AND CARDIAC ARREST FOLLOWING INHALATION OF A DRY CHEMICAL FIRE EXTINGUISHER, Doyon S, McGrath JM. 39. EVALUATION OF DISEASE SEVERITY FOLLOWING ACUTE PARAQUAT POISONING BY APACHE II SCORES, Hung YM. 40. METHYLPHENIDATE INGESTION IN PRE‐SCHOOL CHILDREN: A CASE SERIES, Bailey B, Letarte A, Abran MC. 41. ESCITALOPRAM, A REVIEW OF ADVERSE EFFECTS IN OVERDOSE REPORTED TO SELECT REGIONAL POISON CENTERS, Lindgren KN, Bangh SA, Ling L, Stremski E, Mueller C. 42. NOT NICE TO LICE®—NOT SO NICE TO EYES, Reis K, Hadley C, Scalzo A, Casavant M. 43. A REVIEW OF SEIZURES REPORTED TO THE FDA IN ASSOCIATION WITH USE OF DIETARY SUPPLEMENTS, Meier KH, Haller CA, Olson KR. 44. MASSIVE VENLAFAXINE OVERDOSE RESULTING IN ARRHYTHMOGENIC DEATH, Cumpston K, Chao M, Pallasch E. 45. TREATMENT OF MODERATE TO SEVERE PARAQUAT POISONING WITH VINCRISTINE AND DEXAMETHASONE, Chomchai S, Chomchai C. 46. PEDIATRIC TRIMEDOXIME (TMB4) AND ATROPINE POISONING, Mordel A, Bar Haim S, Bulkobstein M, Berkovitch M, Kozer E. 47. SERUM ENZYMES ACTIVITY IN CASES OF CORROSIVE POISONINGS (CP), Sarmanaev SKh. 48. RETROPERITONEAL HEMORRHAGE AND KIDNEY DAMAGE DUE TO TRAUMA CAUSED BY PLAY‐FIGHTING DURING A COCAINE HIGH, Skanning PG, Christophersen AB. 49. THE MYSTERY ABOUT THE GAS USED FOR THE RELEASE OF THE HOSTAGES IN THE MOSCOW MUSICAL THEATER, Zilker Th, Pfab R, Eyer F, von Meyer L. 50. THE USE OF TABLES FOR PROGNOSIS OF LIFE‐THREATENING STATES REQUIRING ICU HOSPITALIZATION IN CASES OF ACETIC ACID POISONINGS (AAP), Sarmanaev SKh, Akhmetov IR. 51. UNINTENTIONAL PEDIATRIC VITAMIN D INTOXICATION, Barrueto F Jr, Howland MH, Hoffman RS, Nelson LS. 52. CONSERVATIVE MANAGEMENT OF ELEMENTAL MERCURY SEQUESTRATION IN THE APPENDIX, Nañagas KA, O'Connor AD, Potts ME, Rusyniak DE. 53. THIORIDAZINE INDUCED TORSADES DE POINTES TREATED WITH SODIUM BICARBONATE AND TRANSVENOUS PACING, Greene T, Dougherty T. 54. CLONIDINE INGESTION IN CHILDREN, Spiller HA, Colvin JM, Villalobos D, Johnson PB, Anderson DL, Klein‐Schwartz W. 55. RISK FACTORS OF PNEUMONIA DEVELOPMENT IN CASES OF POISONINGS BY ACETIC ACID (AAP), Sarmanaev SKH. 56. TIZANIDINE (ZANAFLEX®) EXPOSURE, Adamson LA, Spiller HA, Bosse GM. 57. FOMEPIZOLE IS NOT SUBSTANTIALLY ELIMINATED BY CONTINUOUS ARTERIOVENOUS HEMODIALYSIS (CAVHD), Schier JG, Shapiro WB, Howland MA, Nelson LS, Hoffman RS. 58. EARLY HEMODIALYSIS IN ACUTE FORMALIN INGESTION, Darkazally N, Judge BS, Rusyniak DE. 59. EPIDEMY OF ACUTE RESPIRATORY ILLNESS LINKED TO USE OF WATER‐PROOFING TEXTILE AND LEATHER SPRAY, Kupferschmidt H. 60. USE OF FLUMAZENIL FOR LORAZEPAM‐INDUCED PARADOXICAL REACTIONS IN CHILDREN, Kent DA, Elko CJ, Gibson J, Robertson WO.
10:15 am–10:45 am Conference Center Room 12:	=	Refreshment Break
10:45 am–12:45 pm Conference Center Room 10:	=	CDC/NIOSH Workshop: Respirators, Moderator: Michael Ottlinger, PhD A Workshop on the Characteristics, Selection and Use of Respirators for the Workplace, Heinz Ahlers, MS, JD, NIOSH The participant at the end of this session should be able to: Describe the role of CDC/NIOSH is respirator research and certification. List the major types of respirators. Compare the characteristics of the various respirators types. Select an appropriate respirator for a given workplace exposure. Discuss the proper use of respirators in the workplace.
10:45 am–11:30 am Hotel Regency Ballroom AB:	=	ACMT Ellenhorn Lecture and Award
11:00 am–12:00 pm Conference Center Room 20:	=	PEC—Tools to Track Education Activity
11:30 am–12:30 pm Conference Center Room 21:	=	AAPCC Managers Committee
11:30 am–12:45 pm Hotel Regency Ballroom AB:	=	ACMT Practice Symposium: Medication Toxicity and Errors and the Medical Toxicologist, Moderator: Charles McKay, MD Hospital Error Monitoring: Lessons Learned, Leslie Boyer, MD, Arizona Poison & Drug Information Center Iatrogenic Narcotic Overdose: The Other Side of Pain Management, Kenneth Kulig, MD, Toxicology Associates, Inc. Regulatory Efforts at Error Reduction: The USP and Other Checkpoints, Wayne Snodgrass, MD, PhD, University of Texas Medical Center The participant at the end of this session should be able to: Identify the potential for system errors in medication prescription and administration. List several high‐risk situations or medications for medical error. Assist in the assembly of a system to prevent medication errors. Identify the key individuals or departments in their area of practice to involve in error reduction. Understand the steps involved in identifying dietary supplement toxicities.
11:30 am–12:30 pm Hotel Regency Ballroom CDE:	=	Specialist in Poison Information Roundtable: Obtaining ABAT Certification, Moderator: Kathy Marquardt, PharmD, CSPI Benefits of Membership in the American Board of Applied Toxicology, Peter Chyka, PharmD, Southern Poison Center American Board of Applied Toxicology Credentials Review Process, Greene Shepherd, PharmD, North Texas Poison Center American Board of Applied Toxicology Examination Overview, Elizabeth Scharman, PharmD, West Virginia Poison Center General Discussion The participant at the end of this session should be able to: Explain the purpose of the American Board of Applied Toxicology. Describe the career opportunities available to diplomates of the American Board of Applied Toxicology. Review the credentialing process and describe what activities can be applied to each section of the application. Describe the areas of toxicology that will be tested and how the exam will be conducted.
12:30 pm–1:30 pm Conference Center Room 21:	=	AAPCC Data Collection Committee
12:45 pm–1:45 pm:	=	Lunch on Own
12:45 pm–1:45 pm Conference Center Room 22:	=	ACMT Business Meeting
1:45 pm–3:45 pm Hotel Regency Ballroom:	=	AACT Symposium: Controversies in Carbon Monoxide Management, Moderator: Jeffery Brent, MD, PhD Hyperbaric Oxygen Therapy in Carbon Monoxide Poisoning, Lindell Weaver, MD, University of Utah A Critical Review of HBO for Carbon Monoxide Poisoning, Nick Buckley, MD, The Canberra Hospital Statistical Considerations of Studies on HBO in Carbon Monoxide Poisoning, Robert Weirs, MD, University of Florida College of Medicine The participant at the end of this session should be able to: Review the treatment of carbon monoxide poisoning. Summarize the controversies regarding the indications for HBO in the patient with CO poisoning. Describe the potential side effects of HBO therapy. Critique the statistical analysis of current CO literature and explain its implications on clinical practice.
1:00 pm–2:00 pm Conference Center Room 20:	=	PEC—Health Literacy
2:00 pm–3:00 pm Conference Center Room 20:	=	PEC—Cultural Competency/Sensitivity
3:15 pm–4:45 pm Conference Center Room 20:	=	PEC—Joint Steering Committee
3:45 pm–5:00 pm Conference Center Room 12:	=	Authors with Posters/Refreshment Break Abstracts #1–60
5:00 pm–5:30 pm Conference Center Room 12:	=	Poster Session I Tear Down
5:00 pm–7:00 pm Conference Center Room 21 A:	=	AACT Occupational/Environmental Section Meeting
5:00 pm–7:00 pm Conference Center Room 21 B:	=	AACT Acute/Intensive Care Section Meeting
5:00 pm–6:00 pm Conference Center Room 21 C:	=	AAPCC Toxicosurveillance Overview
5:45 pm–6:30 pm Conference Center Room 12:	=	Poster Session II Set‐up
6:00 pm–10:30 pm Conference Center Room 22 AB:	=	AAPCC Board of Directors
6:30 pm–8:30 pm:	=	AACT Fellows Reception and Career Recognition Award Presentations

Sunday, September 7, 2003
7:00 am–6:00 pm Conference Center Registration Desk:	=	Registration/Information
7:00 am–8:00 am Conference Center Room 21 A:	=	AACT Interest Group on Envenomations
8:00 am–10:00 am Hotel Regency Ballroom:	=	ACMT Symposium: Current Concepts in Opioid Addiction, Moderators: Suzanne Doyon, MD and Kevin Osterhoudt, MD Addiction and the Brain, Nora Volkow, MD, National Institutes of Health Buprenorphine 101: What Toxicologists Need to Know, Laura McNicholas, MD, PhD, University of Pennsylvania and VA Medical Center The participant at the end of this session should be able to: Describe the neurocircuitry of addiction. Recognize the common pathways for addiction. Distinguish the difference between the neurobiology of tolerance, craving, reinforcement and compulsion. Describe the pharmacology and pharmacokinetics of buprenorphine. Indicate the legal parameters within which buprenorphine should be prescribed. Diagnose and treat acute buprenorphine intoxication. Apply knowledge of acute buprenorphine intoxication to the context of a mixed drug overdose.
8:30 am–10:00 am Conference Center Room 20:	=	PEC—Outreach and Education Strategies for Rural vs. Urban Populations
10:00 am–6:00 pm Conference Center Room 12:	=	Exhibits/Poster Session II Acute/Intensive Care and Poison Centers Abstracts #61–120 61. INTENTIONAL CARDIOACTIVE STEROID POISONING FROM KYUSHIN, A TRADITIONAL JAPANESE MEDICATION, Greller HA, Ravikumar PR, Nelson LS, Hoffman RS. 62. HOMEMADE PLAY DOUGH TOXICOSES IN DOGS: 14 CASES (1998–2001), Barr J, Khan S, McCullough S, Volmer P. 63. TWO CASES OF SEVERE “BRAKE FLUID” POISONING IN THE “MOTOR CITY,” Baltarowich L, Qureshi S, Smolinske S, White S. 64. IMPORTANCE OF THE EARLY PROGNOSIS OF RESPIRATORY DYSFUNCTION INDUCED BY ACUTE POISONINGS, Petrov AN, Sanotsky VI, Davidova EV. 65. TREATMENT OF ANTICHOLINERGIC DRUG INDUCED COGNITIVE DISORDERS: CLINICAL EFFECTS AND PROGNOSIS, Sofronov GA, Sofronov AG. 66. RELIABILITY OF THE GLASGOW COMA SCALE (GCS) FOR POISONING, PATIENTS, Heard K, Bebarta V. 67. EPHEDRINE‐INDUCED TOURETTE SYNDROME, Sharma AN, Olmedo R. 68. USE OF OCTREOTIDE IN SULFONYLUREA POISONING IN A CHILD, Kent DA, Main BA, Friesen MS. 69. A FOUR YEAR REVIEW OF PEDIATRIC LORATADINE INGESTIONS; IMPLICATIONS FOR POISON CENTER REFERRAL GUIDELINES, Manning B, Tai W, Kearney T. 70. A SURVEY OF US POISON CENTER DIRECTORS ON THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSE WITH CARDIOTOXICITY, Cronin KA, Caraccio T, McGuigan M. 71. ATYPICAL PRESENTATION INCLUDING DECEREBRATE POSTURING FROM DIPHENHYDRAMINE (DPH) TOXICITY IN A 23 YR‐OLD, Foresto CM, Caraccio TR, McFee R. 72. ANAPHYLAXIS DURING CROFAB™ ADMINISTRATION, Meier KH, Tsukaoka BT, Dudyala V. 73. SEVERE LACTIC ACIDOSIS: DON'T FORGET PHENFORMIN, Criaco C, Bacis G, Farina ML. 74. INTRACTABLE PRIAPISM ASSOCIATED WITH HERBAL STIMULANTS, Tuckler VE, Barton C, Litner J, Matinez J. 75. NEAR FATAL ACCIDENTAL TRANSDERMAL OVERDOSE OF COMPOUNDED KETAMINE, BACLOFEN, AMITRIPTYLINE, LIDOCAINE, AND KETOPROFEN: A CASE REPORT, Sigillito RJ, Tuckler VE, Van Meter KW, Martinez J. 76. COMPLETION OF WHOLE BOWEL IRRIGATION IN PCC OVERDOSE PATIENTS, Shih RD, Laird D, Ruck B, Marcus SM. 77. INTRACEREBRAL HEMORRHAGE ASSOCIATED WITH INGESTION OF TOBACCO SNUFF, Dahl B, Caravati EM. 78. THE SERIOUS SIDE OF OLANZAPINE OVERDOSE, Rottinghaus D, Bryant S, Harchelroad F. 79. ACCIDENTAL INTRAVENOUS BARIUM SULFATE INFUSION, Rivera W, Hail S, Hall W, Keyes DC, Velez L. 80. SURVIVAL AFTER ETHYLENE GLYCOL OVERDOSE WITH BLOOD PH OF 6.54, Rottinghaus D, Bryant S, Harchelroad FP. 81. LACK OF TOXIC EFFECTS FOLLOWING ACUTE OVERDOSE OF MYCOPHENOLATE, Bebarta V, Heard K, Nadelson C. 82. LACK OF TOXICITY OR SIGNIFICANTLY ELEVATED FORMATE LEVELS FOLLOWING INHALATIONAL ABUSE OF METHANOL CONTAINING SOLVENTS, Bebarta V, Heard K, Delgado J, DeWitt C, Kostic M, Dart R. 83. COMPARISON OF PEDIATRIC USE OF IV AND ORAL N‐ACETYLCYSTEINE, Schmidt R, Jang T, Schmidt L, Mullins M. 84. INADVERTENT INJECTION OF BOTULINUM TOXIN A (BOTOX™) INTO THE INFRAORBITAL AND MENTAL NERVES RESULTING IN DYSPHAGIA, Tsutaoka BT, Olson KR. 85. DELAYED ONSET OF SEIZURES FOLLOWING WELLBUTRIN SR® OVERDOSE, Goldstein RA, Perez A, McKay CA, Roche K. 86. CITALOPRAM OVERDOSE: LATE PRESENTATION OF TORSADES DE POINTES (TDP) WITH CARDIAC ARREST, Tarabar AF, Hoffman RS, Nelson LS. 87. HYPERGLYCEMIA IN A PEDIATRIC CARBAMAZEPINE OVERDOSE, Cumpston KL, Skrupky R, Pallasch E, Wahl M. 88. EFFECTIVENESS OF OBIDOXIME IN ORGANOPHOSPHATE POISONING, Thiermann H, Worek F, Szinicz L, Eyer P, Zilker T. 89. USE PATTERNS FOR A UNIVERSITY HOSPITAL‐BASED MEDICAL TOXICOLOGY SERVICE, Cox RD. 90. CRITICALLY ILL NIACIN OVERDOSE, Santoni L, Strother JS, Grazer RE, Mularski RA, Bizovi KE. 91. FACTITIOUS DIGOXIN TOXICITY FROM INTERFERENCE WITH AN AUTOMATED IMMUNOASSAY, Aaron CK, Stiles P. 92. NASAL BUTTON BATTERY IMPACTION AS CAUSE OF PERIORBITAL CELLULITIS AND CORROSSIVE TISSUE INJURY, Kirk MA, Baer AB, Holstege CP, Martin ML. 93. AMANTADINE TOXICITY IN A RENAL TRANSPLANT PATIENT, Michalski LS, Hantsch CE, Hou SH. 94. INAPPROPRIATE LAUGHTER: AN ISONIAZID ADVERSE DRUG EVENT, Schier JG, Nelson LS, Hoffman RS. 95. CONFIRMED ISOLATED BUPROPION OD PRODUCING QRS WIDENING, Curry S, Holubek W, Kashani J. 96. PILL IDENTIFICATION: RETHINKING THE POISON CENTER'S ROLE, Muller AA. 97. IMPACT OF BIOLOGICAL/CHEMICAL TERRORISM ON POISON CENTERS, Cantrell FL, Carlson T. 98. COST‐EFFECTIVENESS OF PROMOTION BY POISON CENTERS OF ACTIVATED CHARCOAL IN THE HOME, Wilson L, Van Bebber SL, Kearney TE, Olson KR, Spiller HA 99. POLICIES AND EXPERIENCE OF U.S. POISON CENTERS WITH HOME ADMINISTRATION OF SINGLE‐DOSE ACTIVATED CHARCOAL, Wilson L, Van Bebber SL, Kearney TE, Hiatt PH. 100. RESULTS OF A POISON CENTER SURVEY REGARDING INFORMATION PROVIDED BY HOSPITALS TO SPECIALISTS IN POISON INFORMATION, Stremski E, Powers M. 101. VALIDATION OF A METFORMIN POISON CENTER PROTOCOL: A 48‐MONTH EXPERIENCE IN TODDLERS, LoVecchio F, Klemens J, Curry SC, Wallace KW. 102. A PROSPECTIVE POISON CENTER EXPERIENCE OF SUSTAINED‐RELEASE BUPROPION OVER 40‐MONTHS IN CHILDREN, LoVecchio F, Hilder R, Ruha AM. 103. FOUR‐YEAR EXPERIENCE WITH METHOTREXATE EXPOSURES, Lovecchio F, Watts D, Katz K. 104. HELP, I'M PERPLEXED ABOUT APPLICABILITY – ASSESSMENT OF A POISON CENTER'S APPROACH TO MEETING THE HIPAA PRIVACY RULE, Herrington LF, Welch SD, Geller RJ. 105. COMPUTERIZED CUSTOMER SATISFACTION SURVEY, Bennett HKW, Crouch BI, Caravati, EM. 106. MEDICAL ERROR IN POISON CENTER PRACTICE: A PRELIMINARY STUDY, Seifert SA, Jacobitz K, Benson BE. 107. POISON CENTER MEDICAL ERROR DETECTION AND PREVENTION, Seifert SA, Boyer LV, Bronstein AC, Jacobitz K, McNally J. 108. PAEDIATRIC LIDOCAINE (LIGNOCAINE) TOXICITY, Balit CR, Gilmore SP, Isbister GK. 109. REALTIME TESTING OF A RPICS DISASTER PLAN, Mrvos R, Krenzelok EP. 110. UTILIZING POISON CENTER DATA FOR PUBLIC HEALTH SURVEILLANCE, Anderson DL, Miller B, Kassenborg H, Hadidi M, Overbo N. 111. IMPLEMENTATION OF A NOVEL BACKUP SYSTEM FOR POISON CENTERS: PC‐IN‐A‐BOX, Anderson BD. 112. TOXBASE®—MEETING THE INFORMATION REQUIREMENTS OF AN INCREASINGLY DIVERSE USER BASE, Bateman DN, Good AM, Kelly CA. 113. ACCURACY OF CAREGIVERS IN ASSESSING LIQUID MEDICATION SPILLS—EXPANDED INVESTIGATION, Branton T, Ciancaglini P, Benitez J, Lawrence R. 114. SPACE SHUTTLE COLUMBIA DISASTER: UTILIZATION OF POISON CENTERS, Keyes DC, Shepherd G, Borys D, Ellis M, Ryan M, Watson WA. 115. WATER YO‐YO EXPOSURES: AN UNUSUAL TEST OF TESS SURVEILLANCE, Hoffman RS, Ruck B, Caraccio T, Caliva TM, Joshi P, Benitez J, Watson WA. 116. BEWARE OF CANINE GORILLA GLUE™ INGESTIONS—A FIRST REPORT, Lubich C, Mrvos R, Krenzelok EP. 117. PERFORMANCE IMPROVEMENT INTERVENTIONS ON THE RATES OF GASTRIC DECONTAMINATION RECOMMENDED BY A POISON CENTER, Chyka PA, Winbery SL. 118. IMPLEMENTATION OF THE HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) OF 1996 AND THE EFFECTS ON POISON CENTER OPERATIONS, DeGeorge P, Mrvos R, Krenzelok EP. 119. DETERMINING THE FEASIBILITY OF CREATING AND MAINTAINING A CENTRALIZED ANTIDOTE REGISTRY, Cantrell FL. 120. MANAGEMENT OF ACUTE PEDIATRIC LEAD PAINT CHIP INGESTION, Goldstein RA, McKay CA, Burke E, Roche K, Bayer MJ.
10:00 am–10:30 am Conference Center Room 12:	=	Refreshment Break
10:30 am–12:00 pm Conference Center Room 20:	=	PEC—Networking Session “Swap & Share”
10:30 am–12:30 pm Conference Center Room 10:	=	ABAT Symposium: Bridging the Gap Between Science and Practice, Moderators: Edward P. Krenzelok, PharmD and Bruce Anderson, PharmD Excitatory Amino Acid Receptors, William Dribben, MD, Washington University School of Medicine GABA A & GABA B Receptors, Michelle Ruha, MD, Medical Toxicology Fellowship, Banner Health Opiate/Opioid Receptors, Thomas Kearney, PharmD, California Poison Information System—SF The participant at the end of this session should be able to: Discuss mechanisms of withdrawal associated with substances of abuse. Describe the relationships between withdrawal mechanisms and treatment options. Identify advances in the treatment of withdrawal associated with substances of abuse.
10:30 am–12:30 pm Conference Center Room 23:	=	CDC/NIOSH Workshop: Health Hazard Evaluation, Moderator: Michael Ottlinger, PhD CDC/NIOSH Health Hazard Evaluation Program: Practical Evaluations of Workplace Toxins, Bruce Bernard, MD, NIOSH 1‐Bromopropane: An Emerging Toxic Solvent?, Jeffery Nemhauser, MD, NIOSH The participant at the end of this session should be able to: Describe how NIOSH approaches a Health Hazard Evaluation involving an occupational hazard. Discuss the limitations of a Health Hazard Evaluation. List the known or suspected toxicity of 1‐bromopropane exposure.
10:30 am–12:30 pm Conference Center Room 11:	=	Advanced Chemical Warfare/Terrorism Agents Workshop: Part I, Moderator: Introduction, Donna Seger, MD, Vanderbilt University Clinical Toxicology's Role in Responding to Chemical Weapon Terrorism, Philip Edelman, MD, CDC Office of Terrorism Preparedness and Emergency Response Halabja: The Large‐Scale Use of Chemical Weapons Against a Civilian Population, Edward Cetaruk, MD, University of Colorado Health Sciences Center Pathophysiology of Phosgene‐Induced Lung Injury, To Be Arranged
12:30 pm–2:30 pm Hotel Regency Ballroom:	=	Luncheon Presentation
2:30 pm–5:30 pm Offsite:	=	A Tale of Poisons Tour reservations required
2:30 pm–4:30 pm Conference Center Room 10:	=	The Year In Toxicology: Forensics and Basic Science, Moderator: Jerry Leikin, MD Molecular Autopsy, Steven Wong, PhD, Medical College of Wisconsin The participant at the end of this session should be able to: Discuss the concept of the molecular autopsy. Critique the relevance of molecular autopsy in cause of death determinations.
2:30 pm–4:00 pm Conference Center Room 11:	=	ASCEPT Symposium: Marine Toxicology, Moderators: Andrew Dawson, MD and Ian Whyte, MD Seafood Poisoning: Why not to Eat Fish on Monday, Robert Dowsett, MD, Westmead Hospital Venomous Fish, Shellfish and Other Oddities, Geoff Isbister, MD, Newcastle Mater Misericordiae Hospital Jellyfish Envenomation: New Diseases and New Treatment, Mark Little, MD, Sir Charles Gairdner Hospital The participant at the end of this session should be able to: Discuss the reasons why seafood poisoning may increase in frequency and geography. Characterise the clinical presentation of the different syndromes of seafood poisoning. Critically appraise the current evidence for management of seafood poisoning. Recognise the clinical presentation of Irukandji syndrome in relation to other jellyfish envenomation. Assess the relative values of various first aid recommendations for jellyfish envenomation. Describe the range of severity of marine stinger envenomation and consequently management required.
2:30 pm–4:00 pm Conference Center Room 23:	=	CDC/NIOSH Workshop: Dermal Toxicology, Moderator: Michael Ottlinger, PhD A Rash Overview of Occupational Skin Diseases—Breaking the Epidermal Barrier, Boris Lushniak, MD, MPH, NIOSH Occupational and Environmental Exposures to the Skin: Relevance to Public Health, Mark Boeniger, MS, CIH, NIOSH The participant at the end of this session should be able to: Describe the importance of the skin as a barrier to environmental toxins. List the variety of occupational skin conditions that can affect the barrier function of the skin. Detail which resources are available to search out more information on occupational skin diseases. Characterize the ways that skin contact with its outside environment can adversely affect health. Discuss the prevalence of dermatitis and consequences of systemic absorption, especially for working people who may be exposed to a wide variety of chemical and physical insults in their workplace. Appreciate the impact of these adverse conditions in terms of the many costs, some obvious and some not so. Relate the sources of information that could be useful for recognizing, evaluating and preventing dermal exposures.
2:45 pm–4:15 pm Conference Center Room 20:	=	PEC—Sub‐Committee Meetings
4:30 pm–6:00 pm Conference Center Room 12:	=	Authors with Posters—Session II Abstracts #61–120
6:00 pm–8:00 pm Hotel Regency Ballroom:	=	Toxicology Quiz Bowl
6:00 pm–6:30 pm Conference Center Room 12:	=	Poster Session II Posters Removed
6:45 pm–7:30 pm Conference Center Room 12:	=	Poster Session III Set‐up

Monday, September 8, 2003
7:00 am–5:30 pm Conference Center Registration Desk:	=	Registration/Information
7:00 am–8:00 am Conference Center Foyer:	=	Continental Breakfast
8:00 am–10:00 am Conference Center Room 10:	=	IPCS Symposium: Surveillance Systems for Improving Public Health Responses to Chemical Risks, Moderator: Timothy Meredith, MD Global Surveillance of Adverse Drug Reactions, Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring Global Surveillance and Preparedness and Response Mechanisms for the Deliberate and Accidental use of Chemicals to Cause Harm, Stephen Palmer, University of Wales College of Medicine Systems for Monitoring and Collecting Observational and Exposure Information on Humans—Opportunities for Improvements, Lesley Onyon, International Programme on Chemical Safety The participant at the end of this session should be able to: Identify the key systems and any gaps for monitoring the safety of pharmaceuticals, pesticides, industrial chemicals and those used in consumer chemicals. Describe the current approaches being taken globally to strengthen international actions for the preparedness and response to the accidental release or the deliberate use of chemical agents to cause harm. Differentiate between surveillance systems and those used for raising alerts and warning signals. Propose some of the key benefits that might result from the increased use of human toxicology data for chemical risk assessment purposes.
8:00 am–9:00 am Conference Center Room 23:	=	CDC/NIOSH Workshop: Resources in Clinical Toxicology, Moderator: Michael Ottlinger, PhD An Overview of CDC/NIOSH: Research, Resources and Information in Occupational Safety and Health, Michael Ottlinger, PhD, CDC/NIOSH The participant at the end of this session should be able to: Discuss the mission, structure and place of CDC/NIOSH in the occupational safety and health arena. Outline the scope of research at NIOSH. Explain the multidisciplinary nature of the NIOSH research team using specific examples from current and past projects. Describe the opportunities for NIOSH to collaborate/partner with other organizations. Review the help available at NIOSH for health and safety or healthcare professionals, industry, labor and workers.
8:00 am–10:00 am Regency Ballroom CDE:	=	Year in Toxicology: Clinical Perspective, Moderator: Jerry Leikin, MD Intravenous N‐Acetylcysteine, Richard Dart, MD, Rocky Mountain Poison and Drug Center Low Level Lead Exposure—New Data on Its Clinical Effects, Michael Kosnett, MD, University of Colorado Health Sciences Center The participant at the end of this session should be able to: Outline the dosing and indications for the use of intravenous n‐acetylcysteine. Monitor for the adverse effects of intravenous n‐acetylcysteine. Critique that data on the effects of low level lead on neurologic development and renal function.
8:30 am–10:00 am Hotel Regency Ballroom AB:	=	CAPCC Symposium: Common Conundrums—Frustrating Issues in Toxicology, Moderator: Ingrid Vicas, MD Irritating Toxicology Truisms, Wesley Palatnick, MD Ten Drug Interactions that Frighten Me the Most, David Juurlink, MD, Sunnybrook and Women's College of Health Sciences Centre What is the Optimal Dose of Activated Charcoal?, Milton Tenenbein, MD, Children's Hospital Manitoba To Dream the Impossible: Preventing Accidental Ingestions in the Adult, Ingrid Vicas, MD, Foothills Medical Centre The participant at the end of this session should be able to: Differentiate between the facts & the fiction around some common beliefs in toxicology. Highlight some selected and potentially serious drug–drug interactions involving commonly used medications. Critique the evidence supporting the various recommendations for activated charcoal dosing. Describe the optimal dose of activated charcoal. Discuss the challenge of poison prevention in adults and prioritize strategies to address this issue.
8:30 am–10:00 am Conference Center Room 20:	=	PEC—Community Organization Partnership Building
9:00 am–10:00 am Conference Center Room 24 C:	=	AACT Section on Chemical Terrorism
10:00 am–10:30 am Conference Center Room 12:	=	Refreshment Break
10:00 am–4:30 pm Conference Center Room 12:	=	Exhibits/Poster Session III Poison Centers, Envenomations, Education and Prevention, Epidemiology, Mushrooms and Plants Abstracts #133–192 133. HOUSEHOLD MERCURY (Hg) SPILLS: VARIATION IN POISON CENTRES (PC): HAS ANYTHING CHANGED?, Button G, Vicas I. 134. CHARACTERIZING THE INFORMATION SPECIALIST (IS)‐MEDICAL TOXICOLOGIST (MT) CONSULTATION INTERACTION, Vicas IMO. 135. MULTIPLE COMMUNICATIONS FOR POISON CENTERS DURING MASS CHEMICAL EXPOSURE, Kirk MA, Dobmeier SG, Holstege CP, Kell SO. 136. OF FIRST RESPONDER AND HEALTH DEPARTMENT OFFICIAL'S KNOWLEDGE OF POISON CENTER SERVICES, Holstege CP, Horn JR, Horn SM, Kell SO, Baer AB, Kirk MA. 137. EVALUATION OF A TV AD CAMPAIGN PROMOTING POISON CENTRE (PC) AWARENESS, Vicas I, McGrath‐Hill C. 138. THE EFFICACY OF ANTIVENIN FOR RUSSELL'S VIPER SNAKEBITE, Hung DZ, Yu YJ. 139. LONG‐TERM OUTCOMES FOLLOWING RATTLESNAKE ENVENOMATIONS: A PRELIMINARY STUDY, Klemens J, LoVecchio F, Thole D, Stabnau K, Klemens A, Randall K. 140. PROSPECTIVE STUDY OF CENTIPEDE STINGS IN AUSTRALIA, Balit CR, Harvey MS, Isbister GK. 141. SUNBURST TARANTULA (PTERINOCHILUS MURINUS) ENVENOMATION, Seifert SA. 142. NEUROTOXIC‐INDUCED RESPIRATORY DETERIORATION REFRACTORY TO CROFAB AFTER RATTLESNAKE ENVENOMATION, Richardson WH, Tong TC, Ly BT, Williams SR, Clark RF. 143. RATTLESNAKE ENVENOMATION TO THE FACE OF AN INFANT, Richardson WH, Barry JD, Tong TC, Williams SR, Clark RF. 144. INTRAVENOUS INJECTION OF RATTLESNAKE VENOM, Blair HW, Ramsey RP, Morgan DL. 145. REPTILE ENVENOMATION 20‐YEAR MORTALITY AS REPORTED BY U.S. MEDICAL EXAMINERS, Morgan B, Lee C, Damiano L, Whitlow K, Geller RJ. 146. EFFECTIVENESS OF DELAYED USE OF CROTALIDAE POLYVALENT IMMUNE FAB (OVINE) ANTIVENOM, Bebarta V, Dart R. 147. PEDIATRIC RATTLESNAKE ENVENOMATION WITH NEUROTOXICITY REFRACTORY TO TREATMENT WITH CROTALINE FAB ANTIVENOM, Goto CS, Gutglass DJ, Richardson WH, Ly BT, Offerman SR, Clark RF. 148. HOUSEHOLD PRODUCT LABELING—INADEQUACIES ABOUND, Cantrell FL, Manoguerra AS. 149. THERAPEUTIC ERRORS WITH CALCIUM CHANNEL BLOCKERS. WHO? WHAT? WHERE? AND WHY?, Manoguerra AS, Cantrell FL. 150. PHARMACY STUDENTS AS POISON PREVENTION EDUCATORS, Hunter H, Crouch BI, Caravati EM. 151. IS MASS‐MAILING AN EFFECTIVE FORM OF PASSIVE POISON CENTER AWARENESS ENHANCEMENT?, Krenzelok EP, Mrvos R. 152. ANIMAL EXPOSURES AND THEIR IMPLICATIONS FOR ONE POISON CENTER, Tarantino ML, Vajani M, Parramore CS. 153. EFFECT OF EDUCATION ON CHILDREN AGE 0–6 IN A SMALL MIDWESTERN CITY: MORE CALLS TO REGIONAL POISON CENTER; FEWER CALLS ORIGINATING FROM HEALTH CARE FACILITIES (HCF), Wahl M, LeMaster J, Malinowski R. 154. PARACETAMOL (ACETAMINOPHEN) OVERDOSE IN THE UNITED KINGDOM; WHERE DO PATIENTS OBTAIN THE TABLETS?, Greene SL, Leman P, Kerins M, Whelan K. 155. HIGH RISK OF PARAFFIN EXPOSURE IN ORTHODOX JEWISH CHILDREN, Hoffman RJ, Morgenstern SS, Hoffman RS, Nelson LS. 156. MEDICATION ERROR LEADS TO PSEUDOTUBERCULOSIS EPIDEMIC, Perrone J, Behrman A, Kearney M, Dragoni D, DeRoos F. 157. “HOSPITAL ANTIDOTE STOCKING: ARE WE READY?,” Ryan ML, Arnold TC. 158. A NATION‐WIDE CONSULTATIVE NETWORK BETWEEN MEDICAL TOXICOLOGY FELLOWSHIP PROGRAMS AND ATSDR REGIONAL OFFICES, Wax P, Nelson L, Kosnett M. 159. OVER‐THE‐COUNTER SALES OF ANTIBIOTICS IN ETHNIC STORES—A CAUTION FOR ANTIBIOTIC MISUSE IN ASIAN POPULATION, Kang‐Yum E, Chiang W, McGuigan M, Caraccio T. 160. HERBAL CONTENTS IN HIP DRINKS NOT SO SOFT, Kang‐Yum E, Yang D, Chiang W, McGuigan M, Caraccio T. 161. COMMUNICATIONS STRATEGY FOR HEALTH EDUCATORS WORKING WITH LOW‐ENGLISH PROFICIENCY LOW‐INCOME HISPANIC CONSUMERS, Simeonov IM, Heard SE. 162. A DOCUMENTED ASSOCIATION OF POISON CONTROL CENTER MEDIA INTERACTIONS AND CARBON MONOXIDE CALLS, Bayer M, Hanoian A, Caperino Crean L. 163. CAN AAPCC TESS BE USED TO DETERMINE THE IMPACT OF FOCUSED PUBLIC POISON EDUCATION EFFORTS?, Krenzelok EP, Watson WA. 164. PATIENT SAFETY—FROM ADVERSE DRUG EVENTS TO HOSPITAL POLICY CHANGE, Anderson J, Seidl E, Fera T, Rottinghaus D, Harchelroad F. 165. TIME SAVING ARCHIVE FOR EDUCATORS, Kell S, Dagenais J, Farrar R, Holstege C. 166. PATIENT SAFETY ISSUES—UTILIZATION OF PHARMACY SATELLITES TO DELINEATE ADVERSE DRUG EVENTS, Laird M, Stipio T, Wieloch L, Fera T, Harchelroad F. 167. EFFECT OF A CARBON MONOXIDE ALARM REGULATION ON CO POISONING, Tomaszewski C, Lavonas E, Kerns R, Rouse A. 168. PREVALENCE OF POISONING IN CHILDREN 6 AND UNDER: A QUANTITATIVE SURVEY OF ONE STATE, Simeonov IM, Heard SE. 169. TESTING SPANISH LANGUAGE MATERIALS WITH LOW‐INCOME PARENTS: WHAT WORKS?, Giraldo GP, Simeonov IM, Heard SE. 170. EPIDEMIC CARBON MONOXIDE POISONING DESPITE A CO ALARM LAW, Lavonas E, Tomaszewski C, Kerns W, Blackwell T. 171. A PROFILE OF CALLS TO A POISON INFORMATION CENTER REGARDING OLDER ADULTS, Skarupski K, Krenzelok E, Mrvos R. 172. PAROXETINE EXPOSURES: FIVE‐YEAR ANALYSIS OF UNINTENTIONAL INGESTIONS IN THE PEDIATRIC POPULATION REPORTED TO THE TEXAS POISON CENTER NETWORK, Baker SD, Vincent CB, Morgan DL. 173. EPIDEMIOLOGY OF CARBON MONOXIDE (CM) POISONINGS IN UFA, Sarmanaev SKh, Samolova RG, Aidarova LF. 174. DANGEROUS DRUGS—AN ANALYSIS OF 142 FATALITIES DUE TO POISONING IN NORTHERN GERMANY, Schaper A, Renneberg B, Desel H. 175. RESPONSE TO A SUSPECTED WEAPON OF MASS DESTRUCTION VICTIM, Schwartz MD, Geller RJ, Morgan BW, Whitlow KS, Thomas JD, Patel MM. 176. EXCESS FATALITY FROM DESIPRAMINE AND DOSAGE RECOMMENDATIONS, Amitai Y, Frischer H. 177. ALPRAZOLAM IS RELATIVELY MORE TOXIC THAN OTHER BENZODIAZEPINES IN OVERDOSE, Isbister GK, O'Regan L, Sibbritt D, Whyte IM. 178. COMPARISON OF PRE‐9/11 AND POST‐9/11 RATES OF NERVE AGENT ANTIDOTE STOCKING IN METROPOLITAN HOSPITALS, Burda AM, Pallasch E, Metz J, Wahl M. 179. NEWSPAPER IMPACT ON POISON CENTER EXPOSURE CALL VOLUME, Mycyk MB, Dimaano JQ, Feier C, Leikin JB. 180. A RETROSPECTIVE ANALYSIS OF CARDIOACTIVE STEROID POISONING, Kirrane BM, Barrueto F Jr., Hoffman RS, Nelson LS, Cotter BW. 181. A STUDY OF THE GENETIC POLYMORPHISM OF DELTA AMINOLEVULINIC DEHYDRATASE (ALAD) IN THAI LEAD EXPOSURE WORKERS, Wanananukul W, Sura T, Salaitanawatwong P. 182. MEDICINAL USE OF COCAINE: A SHIFTING PARADIGM OVER 25 YEARS, Long H, Greller H, Mercurio‐Zappala M, Nelson LS, Hoffman RS. 183. ACETAMINOPHEN POISONING: AN INTERNATIONAL COMPARISON, Balit CR, Hartley V, Shieffelbien L, Temple W, Fountain J, Jones AL, Dargan P. 184. A CHARACTERIZATION OF POISONINGS IN THE ELDERLY, Vo ML, Caraccio TR, Mofenson HC. 185. ANALYSIS OF ADVERSE DRUG REACTIONS (ADR) REPORTED TO A REGIONAL POISON CENTER (RPC), Caraccio TR, McFee R, Mofenson HC. 186. HOSPITAL ANTIDOTE STOCKING SUBSEQUENT TO THE 2001 TERROR ACTS, Roche K, McKay CA, Bayer MJ. 187. OUTCOMES OF A TV AD CAMPAIGN PROMOTING POISON CENTRE (PC) AWARENESS, Vicas I. 188. A NEW MEASUREMENT TOOL FOR EVALUATION OF PC FUNCTION, Vicas I, McGrath‐Hill C. 189. AMINOTRANSFERASES AS MARKERS IN AMANITA PHALLOIDES POISONINGS, Petkovska L, Pereska Z, Naumovski J, Bozinovska C, Naumov I, Babulovska A. 190. COCOA BEAN MULCH AS A CAUSE OF METHYLXANTHINE TOXICOSIS IN DOGS, Hansen S, Trammel H, Dunayer E, Gwaltney S, Farbman D, Khan S. 191. PONTINE STROKE AFTER ACUTE WHITE HELLEBORE POISONING, Rottinghaus D, Kurta D, Krenzelok EP, Harchelroad FP. 192. WITHDRAWAL SYMPTOMS AFTER VALERIAN CESSATION, Wiener SW, Hoffman RS, Nelson LS.
10:00 am–11:00 am Conference Center Room 20:	=	PEC—Sub‐Committee Meeting
10:30 am–12:00 pm Hotel Regency AB:	=	Platform Session 1: Venoms and Drug Abuse Abstracts #121–126 121. FASCIOTOMY WORSENS MYONECROSIS AND HEMORRHAGE IN A PORCIONE MODEL OF INTRAMUSCULAR INJECTION OF CROTALINE VENOM, Tanen DA, Danish DC, Grice G, Riffenburgh RF, Clark RF. 122. CLINICAL EFFECTS OF WOLF SPIDER BITES IN AUSTRALIAN, Isbister GK, Framenau VW. 123. SUBCUTANEOUS INJECTION OF CROTALINE FAB ANTIVENOM FOR THE TREATMENT OF RATTLESNAKE ENVENOMATION IN A PORCINE MODEL, Offerman SR, Barry JD, Richardson WH, Tong T, Tanen DA, Bush SP, Clark RF. 124. A DOSE‐RESPONSE EVALUATION OF THE GHB PRECURSOR, TETRAHYDROFURAN, Quang LS, Vo T, Maher TJ, Shannon MW. 125. MYOCARDIAL HYPERTROPHY IN USERS OF MDMA (METHYLENEDIOXYMETHAMPHETAMINE), Lu H, Kirkland PD, Heninger MM, Wright DW, Miller MA, Patel M. 126. DETERMINATION OF GAMMA HYDROXY BUTYRATE IN STRIATAL DIALYSATES OF RATS TREATED WITH 1,4‐BUTANEDIOL, Shah PP, Bohlke M, Quang LS, Maher TJ. The participant at the end of this session should be able to: Describe the effect of fasciotomy on myonecrosis and hemorrhage in intramuscular injection of crotaline venom. Characterize the clinical effects of wolf spider bites in Australia. Discuss the efficacy of subcutaneous injection of crotaline Fab antivenom for the treatment of rattlesnake envenomation. Evaluate the dose‐response relationship of the GHB precursor, tetrahydrofuran. Review the incidence of myocardial hypertrophy in users of MDMA (methylenedioxymethamphetamine). Predict the presence of gamma hydroxy butyrate in striatal dialysates of rats treated with 1,4‐butanediol.
10:30 am–12:00 pm Hotel Regency CDE:	=	Platform Session 2: Acute and Intensive Care Abstracts #127–132 127. VASOPRESSIN TREATMENT OF VERAPAMIL TOXICITY IN THE PORCINE MODEL, Barry JD, Durkovitch DW, Richardson WH, Tong TC, Cantrell FL, Offerman SR, Clark RF, Tanen DA, Williams SR. 128. THE CHARACTERISATION AND DEVELOPMENT OF MICROSTRUCTURED CARBONS FOR THE TREATMENT OF DRUG OVERDOSE, Malik DJ, Rielly CD, Inman S, Lily YL, Dargan PI, Jones AL. 129. INHIBITION OF CELLULAR TOXICITY OF OXALATE BY EDTA AND CITRATE, McMartin KE, Guo C. 130. THE EFFECT OF AMIODARONE ON AMITRIPTYLINE POISONED MICE, Barrueto F Jr., Chuang A, Hoffman RS, Nelson LS, Cotter BW. 131. A NOVEL SELF‐CONTAINED HEMOPERFUSION DEVICE FOR THE TREATMENT OF THEOPHYLLINE OVERDOSE IN A SWINE MODEL, Davis E, Perez A, McKay CA. 132. PILOT STUDY: USE OF CALCIUM CHLORIDE TO TREAT HYPERKALEMIA DUE TO ACUTE DIGOXIN TOXICITY IN A SWINE MODEL, Hack JB, Woody JH, Brewer K, Meggs WJ. The participant at the end of this session should be able to: Quantitate vasopressin treatment of verapamil toxicity. Characterize the properties of microstructured carbons for the treatment of drug overdose. Describe the inhibition of cellular toxicity of oxalate by EDTA and citrate. Summarize the effect of amiodarone on amitriptyline toxicity. Review the efficacy of a self‐contained hemoperfusion device for the treatment of theophylline overdose. Discuss the use of calcium chloride to treat hyperkalemia due to acute digoxin toxicity.
12:00 pm–12:30 pm Conference Center Room 21 AB:	=	Lecture by John Howard, MD, MPH Director, NIOSH
12:00 pm–1:00 pm:	=	Lunch on Own
12:00 pm–1:00 pm Conference Center Room 22:	=	AAPCC Town Hall Meeting
12:00 pm–1:00 pm Conference Center 21 C:	=	ABAT Annual Open Meeting
12:00 pm–1:00 pm Conference Room Room 24 AB:	=	ACMT Educational Symposium for Fellows‐In‐Training Luncheon, Moderators: Erica Liebelt, MD and Mark Su, MD Data Collection in Clinical Toxicology, Ian Whyte, MD, Newcastle Mater Hospital The participant at the end of this session should be able to: Identify potential issues with the evidence base of clinical toxicology. Discuss potential issues with the use of randomised controlled trials on clinical toxicology. Summarize the potential value of clinically driven data collection (clinical databases) in clinical toxicology. Review the principles behind population analysis of “sparse data.”
12:30 pm–1:30 pm Conference Center 21 AB:	=	Lunch with the NIOSH Director
12:30 pm–1:30 pm Conference Center Room 20:	=	PEC—Social Marketing
1:30 pm–3:30 pm Conference Center Room 10:	=	EAPCCT Symposium: Controversies in Antidotal Therapy, Moderator: Digoxin Antibodies: How Much and When?, Nicholas Bateman, MD, Scottish Poisons Information Bureau Desferrioxamine, Milton Tenenbein, MD, Director, Manitoba Poison Control Centre Oximes: Which is Best for the Public Protection from Nerve Agents?, Allister Vale, MD, National Poisons Information Service, Birmingham The participant at the end of this session should be able to: Explain how each antidote works. Discuss the uncertainties affecting use of these antidotes. List the correct uses of these agents.
1:30 pm–3:30 pm Conference Center Room 23:	=	NLM Symposium: Using the Web to Access Clinical Toxicology Information, Moderator: Philip Wexler Toxicology Information Resources at the National Library of Medicine, Philip Wexler, TEHIP, NLM, NIH A Medical Toxicologist's Perspective on Web Resources, Scott Phillips, MD, Toxicology Associates Specialized Information Resources from CCOHS and other Web Sites, Bob Whiting, Canadian Centre for Occupational Health and Safety The participant at the end of this session should be able to: Distinguish the resources relevant to clinical toxicology and poisoning/poisons at the National Library of Medicine and its Toxicology and Environmental Health Information Program. Describe the subject matter of NLMs toxicology and environmental health files, including which files to approach for which questions. Determine how to formulate search strategies in TOXNET and other NLM files, including options for refining searches and displaying/downloading data. Recognize other Web resources in areas relevant to clinical toxicology, including occupational safety and health. Determine problem solving techniques to use as a clinical toxicologist gathering information from the Web. Assess which Web tools have greater or lesser value, and in which situations, from a clinical toxicology perspective.
1:30 pm–3:30 pm Conference Center Room 11:	=	Advanced Chemical Warfare/Terrorism Agents Workshop: Part II, Moderator: A Review of Current Antidotes for the Treatment of Nerve Agent Poisoning, Allister Vale, MD, National Poisons Information Service, Birmingham New Developments in Pre‐Treatment and Therapy of Nerve Agent Poisoning, Paul Lundy, PhD
1:30 pm–2:30 pm Conference Center Room 20 AB:	=	PEC—Updates on Public Education Initiatives for 2004
1:30 pm–2:30 pm Conference Center Room 20 C:	=	PEC—Increasing PC Utilization by Health Care Professionals
3:30 pm–5:00 pm Conference Center Room 12:	=	Authors with Posters/Refreshment Break Abstracts #133–192
3:00 pm–4:00 pm Conference Center Room 20 C:	=	PEC/NACCT Planning Meeting
5:00 pm–7:00 pm Conference Center Room 10:	=	Toxicology History Society, Moderator: John Trestrail, III, RPh Famous Chicago Poisonings, Steven Aks, MD, University of Illinois Timothy Erickson, MD, University of Illinois, Dept of Emergency Medicine, Frank Paloucek, PharmD, University of Illinois Watching the Changing Toxicology World Through the Dreisbach Window, John Trestrail, III, RPh, DeVos Children's Hospital Regional Poison Center Femme Fatal: Beyond the Myth, Mystique and Men of Lucretia Borgia, Robin McFee, DO, MPH, Nova Southeastern University Movie Toxicology, Howard McKinney, PharmD, University California Davis Medical Center Methanol Poisoning in Atlanta, Brent Morgan, MD, Emory University The participant at the end of this session should be able to: Discuss the details of the Lake Nyos environmental disaster. Discuss how Dreisbach made a significant contribution to the literature of toxicology. Describe some of the famous and infamous poisoning incidents associated with Chicago. Discuss how poisons have been accurately or inaccurately portrayed in the movies. Discuss the environmental disaster of methanol poisoning in a major American city. Discuss the reality behind the story of Lucretia Borgia.
5:00 pm–6:00 pm Conference Center Room 11:	=	CDC/NIOSH Workshop: Hexavalent Chromium Moderator: Michael Ottlinger, PhD Occupational Exposure to Hexavalent Chromium, Kathleen MacMahon, DVM, NIOSH Clinical Toxicology of Hexavalent Chromium, Jefferey Nemhauser, MD, NIOSH The participant at the end of this session should be able to: Characterize the diversity of occupational exposures to hexavalent chromium. Relate the proposed mechanism of hexavalent chromium toxicity. Describe the cohorts of hexavalent chromium workers that provide the basis for lung cancer risk assessments. Evaluate the clinical toxicology of hexavalent as it relates to lung cancer.
5:00 pm–5:30 pm Conference Center Room 12:	=	Poster Session III Posters Removed
7:00 pm–10:00 pm Hotel Regency Ballroom:	=	President's Reception/Dinner (Sponsored by McNeil Consumer Products Company)

Tuesday, September 9, 2003
7:00 am–4:30 pm Conference Center Meeting Office:	=	Speaker Ready Room
7:00 am–8:00 am Conference Center Room 12:	=	Poster Session IV Set‐up
7:00 am–5:00 pm Conference Center Registration Desk:	=	Registration/Information
7:00 am–8:00 am Conference Center Foyer:	=	Continental Breakfast
8:00 am–10:00 am Conference Center Room 10:	=	SPI Symposium: Inhalant Abuse, Moderator: Kathy Marquardt, PharmD Inhalant Abuse, Daniel Rusyniak, MD, Indiana University Medical School The participant at the end of this session should be able to: Understand the scope of the problem of inhalant abuse. Identify clues that may indicated the presence of inhalant abuse. Identify methods by which inhalants are abused. Recognize the four major classes of inhalants that are abused. Recognize the unique clinical syndromes associated with the various classes of inhalants. Identify treatments for the various complications of inhalant abuse.
8:00 am–10:00 am Hotel Regency A:	=	AACT Year in Toxicology: Toxicosurveillance, Moderator: Jerry Leikin, MD Informatics and Toxicosurveillance—A Local Perspective, Michael Gillam, MD, The National Center for Emergency Medicine Informatics Jonathan Handler, MD, The National Center for Emergency Medicine Informatics A Global Perspective on Toxicosurveillance, Stephen Palmer, MD, University of Wales College of Medicine The participant at the end of this session should be able to: Discuss the global dynamics of toxicosurveillance. Apply the principles of toxicosurveillance to poison center or emergency department operations.
8:00 am–10:00 am Conference Center Room 23:	=	NLM TOXTOWN
9:00 am–10:00 am Conference Center Room 20 A:	=	AACT Pediatrics Section
9:00 am–10:00 am Conference Center Room 20 B:	=	AACT Medical Legal Interest Group
10:00 am–12:00 pm Conference Center Room 20 C:	=	PEC—Steering Committee Meeting
10:00 am–10:30 am Conference Center Room 12:	=	Refreshment Break
10:00 am–4:30 pm Conference Center Room 12:	=	Exhibits/Poster Session IV: Mushrooms and Plants, Occupational, Laboratory and Forensic, Heavy Metals, Drug Abuse and Basic Science Abstracts #205–265 205. SEVERE TOXIC REACTIONS TO EPHEDRA: NATIONAL TRENDS FROM 1993–2002, Woolf A, Watson W, Smolinske S, Litovitz T. 206. SAGE TEA RELATED CONVULSIONS IN A PEDIATRIC PATIENT, Tong T, Schneir AB, Williams SR, Ly BT, Richardson WR. 207. MISDIAGNOSED FATAL MEADOW SAFFRON POISONING IN A TODDLER, Rauber‐Lüthy Ch, Baer W, Rentsch K, Meier‐Abt A 208. AN OUTBREAK OF FOOD‐BORNE ILLNESS ASSOCIATED WITH PLANT MATERIAL CONTAINING RAPHIDES—CHICAGO, 2003, Watson JT, Jones RC, Siston AM, Diaz PS, Gerber SI, Satzger RD. 209. POISONING BY SUSUMBER BERRIES, Thompson, M, Thornton, M, Verjee, Z. 210. NEUROTOXICITY ASSOCIATED WITH 1‐BROMOPROPANE EXPOSURE, Beck BR, Caravati EM. 211. LEAD DUST TRANSPORT FROM FIRING RANGES ON THE FOOTWEAR OF RECREATIONAL SHOOTERS—A PILOT STUDY, Eisenberg J., Greenberg M. 212. LEVELS OF POLYCHLORINATED DIBENZO‐P‐DIOXINS (PCDDS), POLYCHLORINATED DIBENZOFURANS (PCDFS) AND POLYCHLORINATED BIPHENYLS (PCBS) IN HUMAN MILK AT TWO U.S. LOCATIONS, Wang RY, Needham LL. 213. METHEMOGLOBINEMIA FROM NITRITE‐CONTAMINATED PUNCH, Ringling S, Boo T, Bottei E. 214. VISUAL SIDE EFFECTS FROM BOTULINUM TOXIN TYPE B INJECTIONS, Cumpston KL, Bryant SM, Rezak M, Kim A, Leikin JB. 215. COLLABORATION OF MULTIPLE AGENCIES IN THE MANAGEMENT OF A HOME MERCURY SPILL, Casavant MJ, Hunter A, Maloy R, Deavers D 216. STROKE AND ENVIRONMENTAL LEAD EXPOSURE IN ADULTS: IS THERE AN ASSOCIATION?, Guest, R., Halluska, M., Hendrickson, R., Greenberg, M. 217. RELATIONSHIP BETWEEN ATMOSPHERIC LOW LEVEL OZONE CONCENTRATIONS AND ED VISITS, Mycyk MB, Brand R, Leikin JB. 218. PLANNING HAZARDOUS MATERIALS EMERGENCIES RESPONSE: THE ROLE OF THE POISON CONTROL CENTER, Bacis G, Farina ML. 219. DETECTION OF A TOBACCO‐SPECIFIC CARCINOGEN IN THE URINE OF CHILDREN EXPOSED TO ENVIRONMENTAL TOBACCO SMOKE, Baum CR, Listman DA, Hsiao AL, Carmella SG, Hecht SS. 220. EFFECTS OF MUSTARD GAS EXPOSURE IN PEDIATRIC PATIENTS (LONG TERM HEALTH STATUS OF MUSTARD‐EXPOSED CHILDREN, 14 YEARS AFTER CHEMICAL BOMBARDMENT OF SARDASHT, Khateri S, Ghanei M, Soroush MR, Haines D. 221. OSMOTIC ACTIVITY OF ETHANOL IN SALINE AND SERUM, Suchard JR, Patel AJ. 222. ARTERIAL AND VENOUS DIFFERENCES IN POSTMORTEM MORPHINE CONCENTRATIONS IN HEROIN OVERDOSE DEATHS, McKinney PE, Crandall CS, Zumwalt R, Kerrigan S. 223. MONITORING OF OCCUPATIONAL EXPOSURE TO METHYLENE CHLORIDE: SAMPLING PROTOCOL AND STABILITY OF URINE SAMPLES, Hoffer E, Tabak A, Scherb I, Weiner A, Bentur Y. 224. IN‐VITRO EFFECTS OF QUETIAPINE ON TRICYCLIC ANTIDEPRESSANT IMMUNOASSAYS, Caravati EM, Juenke JM, Crouch BI. 225. ERYTHROCYTE ACETYLCHOLINESTERASE ACTIVITIES ACCORDING TO AGE IN KOREANS, Roh HK, Kang JH, Kwon YS, Leem JH, Kim JS. 226. RAPID CYANIDE DETECTION USING THE CYANTESMO® KIT, Rella JG, Marcus S, Wagner BJ. 227. FALSE POSITIVE ETHYLENE GLYCOL LEVEL, DeWitt C, Palmer R, Phillips S, Dart RC. 228. COMPARISON OF URINARY PARANITROPHENOL AND PLASMA/RBC CHOLINESTERASE MEASUREMENTS IN THE EVALUATION OF DOMESTIC METHYLPARATHION EXPOSURE, Cox RD. 229. CARBARYL INHIBITION OF PLASMA CHOLINESTERASE ACTIVITY, Long H, Kirrane B, Nelson LS, Hoffman RS. 230. EXPOSURE ASSESSMENT OF CHILDREN EXPOSED TO ARSENIC IN AN URBAN PLAYLOT, Mycyk MB, Crulcich M, Mucha A, Evans A, Wuellner J, Hryhorczuk DO. 231. CLINICAL OUTCOMES IN INORGANIC MERCURY SALTS INGESTIONS Petrovski D, Naumovski J, Pereska Z, Cibisev A, Naumov I, Licoska F. 232. A CASE OF SEVERE IATROGENIC BISMUTH POISONING, Dargan PI, Bailey CA, Greene SL, Murray SA, Jones AL 233. BENIGN OUTCOME WITH TOXIC SERUM IRON LEVELS FOLLOWING IV IRON DEXTRAN OVERDOSE IN 3 PATIENTS, Beuhler MC, Wallace KL 234. DARKNESS ON THE EDGE OF TOWN: A RURAL FAMILY MALICIOUSLY POISOINED BY THALLIUM, Cumpston KL, Burk M, Burda A, Pallasch E, Bonfante C, Johnson S, Erickson TB, Hryhorczuk DO. 235. ARSENIC AND LEAD SOIL CONTAMINATION NEAR A HEAVY METAL REFINERY IN THE ANDES MOUNTAINS, Krause E, Nussle P, Santana D, Wilson B. 236. BLOOD LEAD LEVELS IN PEOPLE LIVING NEAR A HEAVY METAL REFINERY: A CAUSE FOR CONCERN AND FURTHER STUDY, Krause E, Nussle P, Santana D, Wilson B. 237. LEAD‐TAINTED HERBAL REMEDY USED FOR DEVELOPMENTAL DELAY, Schier JG, Hoffman RS, Nelson LS 238. CANINE ZINC TOXICOSIS FROM INGESTION OF A DECORATIVE BATHROOM FIXTURE, Volmer PA, Roberts J, Meerdink GL. 239. COMPARISON OF “NORMAL” REFERENCE RANGES FOR SELECTED HEAVY METALS WITH BIOMONITORING EXPOSURE DATA OF US POPULATION, Schwaner RA, Beuhler MC, Wax PM. 240. MERCURY AND CADMIUM TOXICITY IN A HAITIAN VOODOO MINISTER THAT RESULTED IN ACUTE RENAL FAILURE, Tarabar AF, Su M. 241. SMOKING: A NOVEL ROUTE OF OLANZAPINE ABUSE, Wiener SW, Hoffman RS, Nelson LS. 242. TACHYCARDIA AND RHABDOMYOLYSIS AFTER INTENTIONAL INGESTION OF N,N‐DIPROPYLTRYPTAMINE, Dailey RM, Nelson LD, Scaglione JM. 243. “MELLOW YELLOW”—INTENTIONAL ABUSE OF CLOZAPINE, Hadley C, Griffith J, Casavant M. 244. ROLE OF CONTINUOUS ARTERIOVENOUS HEMODIALYSIS (CAVHD) IN METHANOL POISONING, Schier JG, Shapiro WB, Howland MA, Hoffman RS, Nelson LS. 245. THE EFFECT OF ALCOHOL CO‐INGESTION ON PATIENT BEHAVIOUR IN ACUTE DRUG OVERDOSE, Leman P, Greene SL, Kerins M, Whelan K. 246. FATAL COMPLICATIONS OF ECSTASY AND AMPHETAMINE ABUSE, Baltarowich L, Smolinske S, Thomas R. 247. MOONFLOWER ABUSE AND INTOXICATION IN NORTHERN OHIO, Goetz RJ, Siegel EG, Scaglione JM. 248. MONOAMINE OXIDASE INHIBITOR POISONING RESULTING FROM INTERNET INFORMATION ON ILLICIT SUBSTANCES, Brush DE, Boyer EW, Bird SB. 249. SERUM HOMOCYSTEINE LEVELS DO NOT CORRELATE WITH SEVERITY OF ALCOHOL WITHDRAWAL, Chan GM, Su M, Donnelly JG, Hoffman RS, Nelson LS. 250. SURVIVAL AFTER RECREATIONAL IV ADMINISTRATION OF BENZONATATE Weber J, Scalzo A, Tabba M, Thompson M. 251. PROLONGED HALLUCINATIONS FOLLOWING INGESTION OF ALPHA‐METHYL‐TRYPTAMINE, Holstege CP, Baer AB, Kirk MA. 252. COMPARATIVE RATES OF OXYCONTIN ABUSE: ANECDOTAL HIGHS, Hughes AA, Bogdan GM, Dart RC. 253. CYCLOSPORIN PHARMACOKINETICS WITH MULTIDOSE CHARCOAL AFTER A TEN‐FOLD DOSING ERROR, Qureshi, ST, Smolinske S. 254. URINARY SODIUM AND POTASSIUM EXCRETION AS MEASURES OF IBUPROFEN NEPHROTOXICITY, Goddard J, Strachan FE, Bateman DN. 255. DOES FLUMAZENIL PROLONG GHB POISONING?, Satz WA, Lee DC, Greene T, Dougherty T. 256. CYTOFLAVINE IN EXPERIMENTAL TRAUMATIC BRAIN INJURY COMPLICATED WITH ACUTE ALCOHOLIC INTOXICATION, Tsivinsky AD, Shevchuk MK, Savateeva TN. 257. FUNCTIONAL MRI ASSESSMENT OF ORGANOPHOSPHATE POISONING, Bird SB, Dickson EW, Gaspari RJ, Boyer EW, Ferris CF. 258. THE EFFECT OF AMIODARONE ON SURVIVAL IN A MURINE MODEL OF FLUORIDE TOXICITY, Chu J, Su M, Bania TC, Shah A. 259. HIGH‐DOSE MAGNESIUM INDUCES APOPTOTIC NEURODEGENERATION IN THE DEVELOPING MOUSE BRAIN, Dribben WH, Farber NB, Olney JW. 260. GHB, GBL, & 1,4‐BD REDUCE INFARCT VOLUME FROM REPERFUSION INJURY FOLLOWING TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION (MCAO), Quang LS, Sadasivan S, Maher TJ, Shannon MW. 261. NEUROPROTECTIVE EFFECT OF GHB, GBL, & 1,4‐BD ON RAT FOCAL CEREBRAL ISCHEMIA BY PERMANENT MIDDLE CEREBRAL ARTERY OCCLUSION (MCAO), Quang LS, Sadasivan S, Maher TJ, Shannon MW. 262. LABORATORY DETECTION OF ACUTE 1,4‐BD & GHB OVERDOSE BY ROUTINE URINE ORGANIC ACID ANALYSIS, Quang LS, Law T, Boyer EW, Desai MC, Maher TJ, Woolf AD, Shannon MW, Levy HM 263. ABSTRACT WITHDRAWN. 264. EMERGENCY DEPARTMENT CLINICAL COURSE OF OPIATE OVERDOSES, Martin TG, Mount C. 265. THE EFFECTS OF ADENOSINE RECEPTOR ANTAGONISTS ON AMITRIPTYLINE‐INDUCED CARDIOVASCULAR TOXICITY IN RATS, Aygoren O, Kalkan S, Akgun A, Guven H, Tuncok Y.
10:00 am–10:30 am Conference Center Room 24:	=	AAPCC Business Meeting
10:30 am–12:00 pm Hotel Regency A:	=	Platform Session 3: Occupational and Environmental Exposures Abstracts #193–198 193. EFFICACY OF DMSA AND CANA2EDTA VS. BAL AND CANA2EDTA IN ASYMPTOMATIC CHILDREN WITH LEAD POISONING, Paopairochanakorn C, Grzybowski M, White SR, Bhambhani K. 194. CROSS‐SECTIONAL EXPOSURE ASSESSMENT OF ENVIRONMENTAL CONTAMINANTS IN CHURCHILL COUNTY, NEVADA, Belson M, Holmes A, Funk A, Kieszak S, Rubin C. 195. TRANSDERMAL PENETRATION OF THE HERBICIDE 2,4‐D IS ENHANCED BY UV ABSORBERS FOUND IN COMMERCIAL SUNSCREENS, Pont AR, Charron AR, Brand RM. 196. WHOLE BLOOD AND HAIR MERCURY CONCENTRATIONS IN UPPER GREAT LAKES FISHEATERS: TOTAL AND INORGANIC MERCURY, Dellinger J, Gerstenberger S, Dewailly E, Hayes J. 197. A STUDY TO ESTABLISH AN EFFICIENT MEANS FOR DELIVERING ANTIDOTAL THERAPY AT NERVE AGENT DESTRUCTION FACILITIES, Nechiporenko SP, Zatsepin EP. 198. A MURINE MODEL FOR IN VIVO NEUROTOXICITY OF GAMMA‐HYDROXYBUTYRATE (GHB) AND 3,4‐METHYLENEDIOXYMETHAMPHETAMINE (MDMA; ECSTASY), McGowan KF, Quang LS, Sadasivan S, Maher TJ, Shannon MW. The participant at the end of this session should be able to: Compare the efficacy of DMSA and CaNa2EDTA vs. BAL and CaNa2EDTA in asymptomatic children with lead poisoning. Assess the cross‐sectional exposure to environmental contaminants in Churchill County, Nevada. Predict the transdermal penetration of the herbicide 2,4‐D by UV absorbers found in commercial sunscreens. Characterize whole blood and hair mercury concentrations in upper Great Lakes fish eaters. Establish an efficient means for delivering antidotal therapy at nerve agent destruction facilities. Describe the use of a murine model for in vivo neurotoxicity of gamma‐hydroxybutyrate(GHB) and 3,4‐methylenedioxymethamphetamine(MDMA; Ecstasy).
10:30 am–12:00 pm Hotel Regency B:	=	Platform Session 4: Acetaminophen and Laboratory Toxicology Abstracts #199–204 199. PREDICTING HEPATOTOXICITY FOLLOWING ACETAMINOPHEN OVERDOSE: A NOMOGRAM FOR THE POST‐N‐AC ERA, Sivilotti MLA, Yarema MC, Juurlink DN, Good AM, Johnson DW. 200. LATE ACTIVATED CHARCOAL USE IN ACETAMINOPHEN OVERDOSE, Spiller HA, Winter ML, Klein‐Schwartz W, Bangh SA. 201. ACETAMINOPHEN HALF‐LIFE AS A REFERENCE IN CHOOSING SHORTER ORAL N‐ACETYLCYSTEINE THERAPY FOR THE OVERDOSED PATIENTS, Tsai CL, Chang WT, Fang CC. 202. CLINICAL FEATURES OF A REPEAT‐DOSE MULTIPLE‐DAY PHARMACOKINETICS TRIAL OF ACETAMINOPHEN AT 4, 6, AND 8 G/DAY, Gelotte CK, Auiler JF, Temple AR, Lynch JM, Bowen DL. 203. PLASMA REDUCED GLUTATHIONE (GSH) IN ALCOHOLICS RECEIVING MAXIMAL THERAPEUTIC DOSES OF ACETAMINOPHEN, Palmer RB, Green JL, Kuffner EK, Bogdan GM, Slattery JT, Phillips BR, Cole S, Dart RC. 204. EFFICACY OF DIGIBIND VS DIGIFAB IN BINDING CINOBUFOTALIN, Barrueto F Jr, Hirsch ON, Mercurio‐Zappalla M, Hoffman RS. The participant at the end of this session should be able to: Predict hepatotoxicity following acetaminophen overdose using a post‐N‐AC era nomogram. Evaluate the late use of activated charcoal in acetaminophen overdose. Critique acetaminophen half‐life as a reference in choosing shorter oral n‐acetylcysteine therapy for overdosed patients. Contrast the clinical features of a repeat‐dose multiple‐day pharmacokinetics trial of acetaminophen at 4, 6, and 8 g/day. Plasma reduced glutathione (GSH) in alcoholics receiving maximal therapeutic doses of acetaminophen. Compare the efficacy of Digibind vs DigiFab in binding cinobufotalin.
12:00 pm–1:00 pm:	=	Lunch on Own
12:00 pm–10:00 pm Conference Center Room 20AB:	=	AAPCC Board of Directors
1:00 pm–3:00 pm Conference Center Room 10:	=	Advanced Chemical Warfare/Terrorism Agents Workshop: Part III, Moderator: New Medical Countermeasures for the Treatment of Veiscant Agent Poisoning, Thomas Sawyer, PhD Pathophysiology and Histology of Vesicant‐Induced Tissue, Injury To Be Arranged
1:00 pm–2:00 pm Conference Center Room 23:	=	CDC/NIOSH Workshop: Occupational Exposure Limits and their Relationship to Toxicity, Moderator: Michael Ottlinger, PhD Occupational Exposure Limits: A Tutorial, Ralph Zumwalde, MS, NIOSH The participant at the end of this session should be able to: Distinguish the differences among the occupational exposure limits of Federal Agencies and professional organizations. Describe the type of data typically used in developing occupational exposure limits. Discuss the approaches used in evaluating the potential health risks of hazardous substances and how this information is used in deriving occupational exposure limits. Use occupational exposure information to determine actions to take in minimizing the health risk to exposed workers and to formulate appropriate medical monitoring strategies.
1:00 pm–3:00 pm Hotel Regency B:	=	Underwriters Labs Workshop on Carbon Monoxide Detectors, Moderator: Jerry Leikin, MD Emerging Aspects of Carbon Monoxide Detectors and In‐Home Inhalant Detectors, Paul Patty, Underwriters Laboratories The participant at the end of this session should be able to: Summarize recent advances in carbon monoxide and other in‐home gas detectors. Review the current standards for carbon monoxide and other in‐home gas detectors.
3:00 pm–4:30 pm Conference Center Room 12:	=	Authors with Posters Abstracts #205–265
4:30 pm–5:00 pm Conference Center Room 12:	=	Poster Session IV—Posters Removed